Using corticosteroids to reshape the gut microbiome: Implications for inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 21, Issue 5, 2015, Pages 963-972

  Huang, Edmond Y ^a   Inoue, Takuya ^b   Leone, Vanessa A ^a   Dalal, Sushila ^a   Touw, Ketrija ^a   Wang, Yunwei ^a   Musch, Mark W ^a   Theriault, Betty ^c   Higuchi, Kazuhide ^b   Donovan, Sharon ^d   Gilbert, Jack ^c,e,f,g   Chang, Eugene B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e ARGONNE NATIONAL LABORATORY   (United States)

^f MARINE BIOLOGICAL LABORATORY   (United States)

^g ZHEJIANG UNIVERSITY   (China)

Author keywords

animal models of IBD; inflammation in IBD; microbiology of IBD; steroids in IBD

Indexed keywords

BACTERIAL DNA; DEXAMETHASONE; MUCIN 2; RNA 16S; ANTIINFLAMMATORY AGENT; IL10 PROTEIN, MOUSE; INTERLEUKIN 10; MUC2 PROTEIN, MOUSE;

AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLOSTRIDIALES; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DNA ISOLATION; DOWN REGULATION; FECES CULTURE; GENE EXPRESSION; GERMFREE MOUSE; HOST; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE MUCOSA; LACTOBACILLACEAE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECIPIENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE; ANIMAL; C57BL MOUSE; COLON; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; GASTROINTESTINAL TRACT; GENETICS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; KNOCKOUT MOUSE; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLON; DEXAMETHASONE; DNA, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCIN-2; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RNA, RIBOSOMAL, 16S;

EID: 84929088968     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000332     Document Type: Article

References (65)

1. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313-323.
2. Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin Chem. 2013; 59:617-628.
3. Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes?. Nat Rev Immunol. 2010;10:735-744.
4. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science. 2010; 328:228-231.
5. Heimesaat MM, Fischer A, Siegmund B, et al. Shift towards proinflammatory intestinal bacteria aggravates acute murine colitis via Tolllike receptors 2 and 4. PLoS One. 2007;2:e662.
6. Packey CD, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis. 2009;22:292.
7. Bloom Seth M, Bijanki Vinieth N, Nava Gerardo M, et al. Commensal bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe. 2011;9:390-403.
8. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis. 2007;44:256-262.
9. Ohkusa T, Kato K, Terao S, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820-1829.
10. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature. 2012;487:104-108.
11. Forstner JF, Forstner GG. Gastrointestinal mucus. Physiol Gastrointestinal Tract. 1994;2:1255-1283.
12. Tytgat KM, Buller HA, Opdam FJ, et al. Biosynthesis of human colonic mucin: Muc2 is the prominent secretory mucin. Gastroenterology. 1994; 107:1352-1363.
13. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 2002;295:1726-1729.
14. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
15. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
16. Friend DR. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 1998;12:591-603.
17. Scheinman RI, Gualberto A, Jewell CM, et al. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol. 1995;15:943-953.
18. Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol. 1986;14:161-177.
19. Heimdal K, Hirschberg H, SlettebA H, et al. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol. 1992;12:141-144.
20. Lutgendorff F, Akkermans LMA, Soderholm JD. The role of microbiota and probiotics in stress-induced gastrointestinal damage. Curr Mol Med. 2008;8:282-298.
21. O'Mahony SM, Marchesi JR, Scully P, et al. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry. 2009;65:263-267.
22. Huang EY, Leone VA, Devkota S, et al. Composition of dietary fat source shapes gut microbiota architecture and alters host inflammatory mediators in mouse adipose tissue. JPEN J Parenter Enteral Nutr. 2013;37:746-754.
23. Culman S, Bukowski R, Gauch H, et al. T-REX: software for the processing and analysis of T-RFLP data. BMC Bioinformatics. 2009;10:171.
24. Redinbaugh MG, Turley RB. Adaptation of the bicinchoninic acid protein assay for use with microtiter plates and sucrose gradient fractions. Anal Biochem. 1986;153:267-271.
25. Tytgat KM, Bovelander FJ, Opdam FJ, et al. Biosynthesis of rat MUC2 in colon and its analogy with human MUC2. Biochem J. 1995;309:221.
26. Johansson MEV, Phillipson M, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A. 2008;105:15064-15069.
27. Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117-129.
28. CDC. Inflammatory bowel disease (IBD). Available at: http://www.cdc. gov/ibd/. Accessed September 24, 2014.
29. Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases. Gut. 2011;60:1739-1753.
30. Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes. 2012;3:503-514.
31. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
32. Forsythe P, Kunze WA, Bienenstock J. On communication between gut microbes and the brain. Curr Opin Gastroenterol. 2012;28:557-562.
33. Unsal H, Balkaya M, Unsal C, et al. The short-Term effects of different doses of dexamethasone on the numbers of some bacteria in the ileum. Dig Dis Sci. 2008;53:1842-1845.
34. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci. 1998;94:557-572.
35. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004;125:697-706.
36. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242-249.
37. Riedel CU, Foata F, Philippe D, et al. Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. World J Gastroenterol. 2006;12:3729-3735.
38. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 1999;116:1107-1114.
39. Kim YS, Byrd JC. Ulcerative colitis: a specific mucin defect?. Gastroenterology. 1984;87:1193.
40. Nanthakumar NN, Young C, Ko JS, et al. Glucocorticoid responsiveness in developing human intestine: possible role in prevention of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2005;288:G85-G92.
41. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kB activity through induction of IkB synthesis. Science. 1995;270:286-290.
42. Crinelli R, Antonelli A, Bianchi M, et al. Selective inhibition of NF-kB activation and TNF-A production in macrophages by red blood cell-mediated delivery of dexamethasone. Blood Cell Mol Dis. 2000;26:211-222.
43. Blank M, Klussmann E, Kruger-Krasagakes S, et al. Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types. Int J Cancer. 1994;59:301-306.
44. Hanski C, Hofmeier M, Schmitt-Graff A, et al. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol. 1997;182:385-391.
45. Liu JB, Zhang ZX, Xu YJ, et al. Effects of glucocorticoid on airway mucus secretion in asthma: experiment with asthmatic mouse model [in Chinese]. Zhonghua Yi Xue Za Zhi. 2006;86:2491.
46. Sudo N. Stress and gut microbiota: does postnatal microbial colonization programs the hypothalamic-pituitary-Adrenal system for stress response?. Int Congress Ser. 2006;1287:350-354.
47. Sudo N, Chida Y, Aiba Y, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-Adrenal system for stress response in mice. J Physiol. 2004;558:263-275.
48. Neufeld KM, Kang N, Bienenstock J, et al. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterology Motil. 2011;23:255, e119.
49. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31:464-468.
50. Meslin JC, Fontaine N, Andrieux C. Variation of mucin distribution in the rat intestine, caecum and colon: effect of the bacterial flora. Comp Biochem Physiol Part A Mol Integr Physiol. 1999;123:235-239.
51. Deplancke B, Gaskins HR. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr. 2001;73:1131S-1141S.
52. Elinav E, Strowig T, Kau Andrew L, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145:745-757.
53. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179-185.
54. Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature. 2008;455:1109-1113.
55. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220-230.
56. Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102:11070-11075.
57. Hoskins LC. Mucin degradation in the human gastrointestinal tract and its significance to enteric microbial ecology. Eur J Gastroenterol Hepatol. 1993;5:205-213.
58. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol. 1991;70:443-459.
59. Mukhopadhya I, Hansen R, El-Omar EM, et al. IBD-what role do Proteobacteria play?. Nat Rev Gastroenterol Hepatol. 2012;9:219-230.
60. Ramer-Tait A, Overstreet AM, Hostetter J, et al. Colonization with distinct Proteobacteria provocateurs induces multifactorial gastrointestinal inflammation that is regulated by CD4+ T cells: P-194. Inflamm Bowel Dis. 2012;18:S92.
61. de La Serre CB, Ellis CL, Lee J, et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299:G440-G448.
62. Hoffmann C, Hill DA, Minkah N, et al. Community-wide response of the gut microbiota to enteropathogenic Citrobacter rodentium infection revealed by deep sequencing. Infect Immun. 2009;77:4668-4678.
63. Ventura M, O'Flaherty S, Claesson MJ, et al. Genome-scale analyses of health-promoting bacteria: probiogenomics. Nat Rev Micro. 2009;7:61-71.
64. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224-5231.
65. van der Sluis M, Bouma J, Vincent A, et al. Combined defects in epithelial and immunoregulatory factors exacerbate the pathogenesis of inflammation: mucin 2-interleukin 10-deficient mice. Lab Invest. 2008;88:634-642.